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Abstract
Few studies on the biologic and molecular properties of pediatric glioblastoma have been performed. Until now,
differential genomic analysis of CD133+ve and CD133−ve fractions has not been described in pediatric glioma. We
hypothesize not only that the presence of CD133 could be the source of tumor resistance but also that mainte-
nance of this molecule by hypoxia dictates cellular and molecular behavior. From a series of human glioblastoma
biopsies investigated, only one, IN699 (from a pediatric glioblastoma), generated greater than 4% of the total cell
volume as CD133+ve cells. Using this pediatric glioblastoma, containing unprecedented high levels of the putative
brain tumor stem cell marker CD133, as a study model, we report biologic and molecular characteristics of the
parent culture and of CD133+ve and CD133−ve populations derived therefrom under atmospheric and hypoxic
culture conditions. Immunocytochemistry and flow cytometry were performed with antigenic markers known to
characterize neural stem cells and associated glioma behavior. Behavioral analysis was carried out using prolifer-
ation, adhesion, migration, and invasion assays. Cell cycle analysis and array comparative genomic hybridization
were used to assess copy number profiles for parental cells and CD133+ve and CD133−ve fractions, respectively.
With regard to invasion and proliferation, CD133+ve and CD133−ve fractions were inversely proportional, with a
significant increase in invasive propensity within the CD133−ve cells (P < .005) and a significant increase in pro-
liferation within CD133+ve cells (P < .005). Our observations indicate identical genomic imbalances between
CD133+ve and CD133−ve fractions. Furthermore, our research documents a direct link between decreasing
oxygen tension and CD133 expression.
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Introduction
Although brain tumors are the most common solid cancers in chil-
dren, relatively few studies have been performed on the biological
and molecular properties of pediatric glioblastoma (GB). Unlike
adult GB, very little is understood about the mechanisms of tumor-
igenesis in pediatric GB. The cell of origin within pediatric brain
tumors (PBTs) is often unclear [1]. One theory is that PBTs occur
from the transformation of proliferating neural stem cells (NSCs) [2].
Several lines of evidence support this theory; first, PBTs are frequently
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made of multiple cell types, suggesting that they originate from cells
with multilineage potential [3]; second, several PBTs seem to arise
from the subventricular zone, the region of the brain harboring NSCs
[4]; and third, PBTs regularly overexpress genes required to regulate
the self-renewal and proliferation of NSCs [5] or typically display
mutations within these regulatory genes [1]. If PBTs do indeed con-
tain cells displaying stem cell characteristics, it is crucial to know
whether these cells also harbor aberrant properties critical for the
abnormal growth of the tumor [1].
Several groups have identified the existence of a highly tumorigenic
subset of brain tumor cells. Studies have demonstrated a clear associ-
ation between this subset and (i) the expression of stem cell markers
such as Sox-2, Musashi-1, oligodendrocyte transcription marker 2
(Olig-2), and Nestin; (ii) the ability to undergo multipotent cellular
differentiation; and (iii) the capacity to generate neurospheres. CD133
(prominin-1) is a 120-kDa-transmembrane-spanning glycoprotein
consisting of six domains: two N -glycosylated extracellular loops, two
intracellular loops, a cytoplasmic C-terminal domain, and an extra-
cellular N-terminal domain [6]. CD133 was originally identified as a
cancer stem cell (CSC) marker in the hematopoietic system. A distinc-
tive characteristic of this protein is its down-regulation during cellular
differentiation, supported by the understanding that a cell’s glyco-
sylation state differs with alterations to the differentiation and/or
malignancy state [6]. Since its first discovery, CD133, independently
or in combination with other stem cell markers (such as Sox-2, Nestin,
Musashi-1) has been identified in a variety of human tumors including
prostate tumors, breast cancers, colon carcinomas, lung cancers, and
brain tumors. Importantly, significantly higher expression levels of
CD133 in GB have been associated with poor patient prognosis [7].
Furthermore, CD133-positive cells have been identified as more resis-
tant to radiation and standard chemotherapy in comparison to CD133-
negative cells [8–10]. However, the belief that CD133 may act as a
universal marker of CSCs has been met with a high degree of contro-
versy in the neuro-oncology research community, as the precise biolog-
ical role of CD133 has yet to be established.
Poorly vascularized areas, associated with severe oxygen depriva-
tion, are known to be present within solid tumors of the central ner-
vous system (CNS) [11]. The presence of hypoxic tumor cells is
thought to be a major cause of tumor cell resistance to radiotherapy
[12]. The advancement of cancer by hypoxic microenvironments
occurs by the initiation of transcription factors promoting cell survival,
motility, and tumor angiogenesis. The cellular responses instigated by
hypoxia seem to be manipulated by alterations in gene expression [13].
The stabilization of a glioma tumor cell and the cascade of events lead-
ing to this stabilization, as well as alterations in gene expression, occur
through the activation of hypoxic-inducible factors (HIFs). HIFs are
transcription factors crucial for the adaptive response to oxygen tension
[14]. Oxygen microenvironment clearly influences stem cell develop-
ment and maintenance. The most appealing hypothesis to support this
finding is that stem cells may possibly benefit from hypoxic niches
where oxidative DNA damage is reduced [13]. Because of the apparent
complexity of the microenvironment, plus additional factors seemingly
affecting the expression of the CD133 epitope, it is not surprising that
there are contradictory reports in the literature regarding the functional
properties and expression of CD133 [15–17].
The biologic significance of CD133 is contentious; indeed, the
appropriate study model and microenvironment in which to study
this molecule is debatable. We hypothesize not only that, rather than
being a CSC marker per se, the presence of CD133 could be the
source of tumor resistance but also that the maintenance of this
molecule by hypoxia is linked with cellular and molecular behavioral
patterns. Such a hypothesis requires a thorough understanding of the
biologic behavior of CD133+ve and CD133−ve cells with increasing
oxygen tensions. From a series of GB biopsies, we attempted identi-
fication and separation of CD133+ve cells. In all cases, with the
exception of one, CD133+ve cells constituted less than 4% of the total
cell number (data not included). The sole case, IN699 (from a pedi-
atric GB) where levels of CD133+ve cells were high (40% with stan-
dard oxygen conditions and 92% with hypoxia), was used in the
present study to explore the potential link between CD133 and bio-
logic behavior. Using this pediatric GB containing unprecedented
high levels of the CD133 glycoprotein as a study model, we have
attempted to correlate CD133 expression with cellular phenotype
and biologic behavior.
Materials and Methods
Cell Culture
IN699 is a short-term cell culture that was initiated at the Institute
of Neurology, London, and derived from a supratentorial GB in a
treatment-naive 15-year-old adolescent boy as previously described
[18]. For the maintenance of cell culture and generation of neuro-
spheres, cells were grown in Neurobasal A medium (NBM; Fisher
Scientific, Loughborough, United Kingdom) supplemented with
20 ng/ml epidermal growth factor (Sigma-Aldrich, Dorset, United
Kingdom), 20 ng/ml fibroblast growth factor 2 (Sigma-Aldrich),
32 IE/ml heparin sodium salt from porcine intestinal mucosa (Sigma-
Aldrich), 10 μl/ml Glutamax (Fisher Scientific), and 20 μl/ml B27
supplement (Sigma-Aldrich). Although the cells were maintained on
plastic substrate as monolayers and neurospheres (Figure 1), after
high-density culture on a nonadherent substrate, the cells resembled
the classic neurosphere. The cells were routinely propagated until the
in vitro serial passage 20 was reached. Cells were either incubated at
37°C in 5% CO2 and atmospheric O2 (25%) in a standard humidified
incubator (atmospheric conditions) or 5% CO2 and 3% O2 using a
MiniGalaxy-A hypoxic incubator incorporating a nitrogen supply (hyp-
oxic conditions). The appropriate oxygen tension for in vitro culture
conditions was calculated according to the guidelines set by Csete
[19] and Sullivan et al. [20]. It was ensured that exposure to atmo-
spheric oxygen by the hypoxic cell cultures was minimal. To ensure that
the parental cell culture was an appropriate model of which to investi-
gate CD133 owing to the unprecedented high numbers of CD133+ve
cell, an adult GB displaying between 1% and 4% of its total cell popula-
tions CD133+ve was used as a standard (data not shown).
Immunocytochemistry
IN699 as well as CD133+ve and CD133−ve cells derived there-
from were cultured in six-well plates and were fixed with 4% (wt/vol)
paraformaldehyde for 4 minutes, washed in phosphate-buffered saline
(PBS), treated with 10% normal serum for 60 minutes, and stained
with a primary antibody for 60 minutes at room temperature (RT).
The primary antibodies were mouse anti–ganglioside 3 (GD3) (1:150;
Abcam, Cambridge, United Kingdom), mouse anti–acetylated ganglio-
side 3 (1:150; Invitrogen, Paisley, United Kingdom), rabbit anti–
Musashi-1 (1:300; Abcam), rabbit anti–Olig-2 (1:200; Abcam),
rabbit anti–Ki67 (1:100; Abcam), rabbit anti–proliferating cell
nuclear antigen (PCNA, 1:200; Abcam), mouse anti–glial fibrillary
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acidic protein (GFAP, 1:500;Dako, Cambridgeshire, UnitedKingdom),
mouse anti–oligodendrocyte marker 4 (O4, 1:200; Sigma-Aldrich),
mouse anti-Nestin (1:1000; Abcam), mouse anti–neuron-specific βIII-
tubulin (1:500; Abcam),mouse anti–CD133/1 (AC133, 1:200;Miltenyi
Biotec, Surrey,UnitedKingdom),mouse anti–HIF-1α (1:1300; Abcam),
rabbit anti–HIF-2α (HIF-2α) (1:1300; Abcam), rabbit anti-SRY–related
HMG BOX gene 2 (SOX2, 1:1500; Abcam), mouse anti–cluster of
differentiation 15 (CD15) (1:1500; Abcam); each antibody and respec-
tive dilution factor was optimized before experimental use. Appropriate
controls were used for each staining parameter. The cells were washed
in PBS, incubated with the appropriate fluorochrome (1:500) for
30minutes at RT, and treated withHoechst Blue as the nuclear counter
stain. The secondary antibodies used were goat anti–mouse immuno-
globulin G (IgG) 488 (1:500; Invitrogen), goat anti–mouse IgM 488
(1:500; Invitrogen), goat anti–rabbit IgG 488 (1:500; Invitrogen), goat
anti–rabbit IgG 568 (1:500; Invitrogen), and goat anti–rabbit IgM 568
(1:500; Invitrogen). Depending whether the antigenic location was
intracellular or extracellular, the cells were washed in PBS and incubated
for 4 minutes with 0.01% (vol/vol) Triton X-100 (Sigma-Aldrich) for
membrane permeabilization. The cells were inverted and examinedwith
a Zeiss Axio Imager upright fluorescence microscope (Carl Zeiss Ltd,
Hertfordshire, United Kingdom). For sequential antigen detection, the
same procedure was used as previously described for the processing of sin-
gle extracellular and intracellular antigens. However, before the addition
of the nuclear stain, the cells were incubated for 60 minutes at RT with
10% normal serum and subsequently processed for the second antigen.
Flow Cytometry
Cells were harvested using TryplExpress (Invitrogen) and washed
in PBS. A total of 5 × 105 cells were incubated with the appropriate
primary antibody (at a dilution factor outlined by the manufacturer)
at 4°C for 20 minutes. The primary antibodies were mouse anti-GD3
(1:50; Abcam), mouse anti-acetylated ganglioside 3 (1:50; Invitrogen),
mouse anti-CD15 (1:150; Abcam), rabbit anti–Musashi-1 (1:40;
Abcam), rabbit anti–Olig-2 (1:20; Abcam), rabbit anti–Ki67 (1:10;
Abcam), rabbit anti-PCNA (1:20; Abcam), mouse anti-GFAP (1:50,
Dako), mouse anti-Nestin (1:100; Abcam), mouse anti–CD133/1
(AC133, 1:11; Miltenyi Biotec), mouse anti–HIF-1α (1:130; Abcam),
rabbit anti–HIF-2α (1:130; Abcam), rabbit anti–SOX2 (1:150; Abcam);
each antibody and respective dilution factor was optimized before
experimental use. Appropriate controls were used for each staining
parameter. After washing, the cells were labeled with the appropriate
fluorochrome at 4°C for 15 minutes in the dark. The secondary anti-
bodies used were goat anti–mouse IgG 488 (1:500; Invitrogen), goat
anti–mouse IgM 488 (1:500; Invitrogen), goat anti–rabbit IgG 488
(1:500; Invitrogen), goat anti–rabbit IgG 568 (1:500; Invitrogen), goat
anti–rabbit IgM 568 (1:500; Invitrogen). After further washing, the
labeled cells were analyzed using a BD Biosciences FACSCalibur four-
color flow cytometry system (Oxford, United Kingdom), and acquisi-
tion and analysis of data were conducted using CellQuest Pro software
(BD Biosciences). Propidium iodide (BD Biosciences) allowed the live,
positive cell populations to be accurately gated away from necrotic false-
positive cells. For the processing of intracellular antigens, the cells were
suspended in 100 μl of Cytofix/Cytoperm, a fixation/permeabilization
solution (BD Biosciences), for 20 minutes at 4°C before the application
of the primary antibody. The flow cytometry technique enabled the
analysis of both the percentage mean of the cell population expressing
the antigen (percentage-gated expression) and the mean amount of
antigen expression by the positive cells, that is, the overall fluorescence
level of the total cell population (increase in fluorescence fold intensity).
DNA Preparation and Array Comparative
Genomic Hybridization
Genomic DNA was isolated from 1 × 106 cells using a QIAamp
DNA mini kit following the manufacturer’s instructions (Qiagen Ltd,
West Sussex, United Kingdom). DNA copy number analysis was
performed using the Agilent Human Genome Microarray Kit 244A
(Agilent Technologies Ltd, Santa Clara, CA). Labeling and hybridiza-
tion were performed according to the manufacturer’s instructions (Pro-
tocol v1.0 2007; Agilent). Briefly, 2 μg of tumor and sex-matched
control genomicDNA (Promega, Southampton,UnitedKingdom)were
differentially labeled with Cy5-dUTP and Cy3-dUTP, respectively,
using the Agilent Genomic DNA Kit PLUS (Agilent Technologies
Ltd). Labeled products were then column purified. Tumor and control
DNA were pooled with 50 mg of human CotI DNA and hybridized
to the array with rotation for 40 hours at 65°C. A control array was
completed using normal male and female commercially available
DNA (Promega). Array washing was performed according to the
Figure 1. (A) Growth of the parental cell culture established under NSCs conditions and 3% O2 plus 5% CO2. When cultured under
defined stem cell conditions, the parental culture forms true spheres, which are derived from a single cell, as well as some spherically
aggregated clusters (B) representative of the classic neurosphere.
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Agilent protocol. Each array was scanned using the Innopsys Scanner
700 (Cepheid UK Ltd, Derbyshire, United Kingdom) and analyzed
using Imagene and Nexus Copy Number software (BioDiscovery,
El Segundo, CA). The array spots that passed all quality thresholds were
used for lowness normalization, background corrections, and calculation
of log2 dye ratios. Putative chromosome copy number changes were
defined using BioDiscovery’s own Rank Segmentation Algorithm,
which segments the genome into clusters of uniform log2 ratios. A
significance threshold of 1e − 6 determined regional segmentation.
Threshold cutoffs at ±0.2 and ±0.5 indicated loss or gain of one or
two chromosome copies, respectively.
Automated Magnetic Cell Sorting
IN699 cells maintained under hypoxic oxygen tensions were
magnetically labeled with CD133/1 (AC133) antibody (Miltenyi
Biotec, Bergisch Gladbach, Germany) conjugated to a magnetic micro-
bead in 300 μl of automatedmagnetic cell sorting running buffer (2mM
EDTA [Sigma-Aldrich], PBS [Sigma-Aldrich], and 0.5% bovine serum
albumin [BSA]), 100 μl of FcR blocking reagent (Miltenyi Biotec) and
100 μl of CD133 microbeads (Miltenyi Biotec) at 4°C for 30 minutes
in the dark. For magnetic labeling, no more than 1.0 × 108 cells were
used. An automated magnetic cell sorting (Miltenyi Biotec) was used
for the isolation of CD133; the positive and negative populations were
immediately seeded within the appropriate technique and maintained
under hypoxic oxygen tension or analyzed by flow cytometry. The purity
of the CD133-sorted cells when analyzed by flow cytometry with
a FACSCalibur flow cytometry system (Becton Dickinson, Oxford,
United Kingdom) was 99% ± 0.316%. The growth kinetics of the
CD133+ve and CD133−ve cell populations were significantly different
as identified by 5-bromo-2′-deoxyuridine proliferation analysis, with an
increased growth rate observed in the CD133+ve cells as identified in
Figure 8B. With serial passaging, the isolated populations were resegre-
gated to a mixed positive and negative phenotype.
Human Neural Stem Cell Functional Identification
A human NSC functional identification kit (R&D Systems, Ltd,
United Kingdom) was used for the short-term maintenance and dif-
ferentiation of CSCs into neuronal, astrocyte, and oligodendrocyte
lineages by using specially formulated differentiation supplements con-
taining insulin-like growth factor and fetal bovine serum. An antibody
panel composed of mouse anti–human Nestin, mouse anti–human
GFAP, mouse anti–neuron-specific βIII-tubulin, and mouse anti-O4
was used to identify the phenotypes of neural precursors, astrocytes,
neurons, and oligodendrocytes.
Oxygen Tension Time Point Analysis
IN699 cells were transferred from atmospheric oxygen (5% CO2
and atmospheric O2) to hypoxia (5% CO2 and 3% O2). The expres-
sion levels of HIF-1α, HIF-2α, and CD133/1 (AC133) were analyzed
by flow cytometry with a FACSCalibur flow cytometry system (Becton
Dickinson) at the following time points: 0, 24, 48, 72, and 96 hours
with relation to the incubation period with hypoxia.
Cell Cycle Analysis
Cells were dissociated and harvested in PBS containing 2 mM
EDTA (Sigma-Aldrich), washed once with PBS, and fixed in 70%
(vol/vol) ice-cold ethanol for 30 minutes at 4°C. Cells were washed
twice with PBS and incubated with 50 mg/ml propidium iodide
(Sigma-Aldrich) plus 100 μg/ml RNase (Sigma-Aldrich) for 15 minutes
at RT. Stained nuclei were analyzed with a FACSCalibur flow cytom-
etry system and analyzed using a ModFit 2.0 cell cycle analysis program
(Becton Dickinson).
Adhesion Assay
A 96-well plate was coated with 6 μg/ml of fibronectin (Sigma-
Aldrich), vitronectin (Sigma-Aldrich), Geltrex (Gibco, Paisley, UK) or
4 μg/ml of BSA (Sigma-Aldrich) in 50 μl/well 1× Tris-buffered saline
solution (TBS) and incubated overnight at 37°C. Wells were washed
with TBS and blocked with 10 mg/ml of BSA for 30 minutes at
RT. After rinsing, 3 × 104 cells/well was added in 100 μl of TBS
and incubated at 37°C overnight. After rinsing, cell attachment
was quantified with 100 μl/well of substrate/lysis solution (1% Triton
X-100, 6 mg/ml p-nitrophenylphosphatase [New England Biolabs, Inc,
Hertfordshire, United Kingdom] and 50 mM sodium acetate buffer
[Sigma-Aldrich]; pH 5.0), incubated at 37°C for 90 minutes. The
reaction was quenched with 50 μl/well of 1 MNaOH and immediately
read on a FLUOstar OPTIMA plate reader (BMG LABTECH,
Ortenberg, Germany) with a 405-nm filter.
Proliferation Assay
A colorimetric immunoassay kit (Roche Diagnostics, Mannheim,
Germany) was used for the quantification of cellular proliferation
based on the measurement of 5-bromo-2′-deoxyuridine incorporated
during DNA synthesis. To analyze the proliferation indices (PIs) in
the presence of extracellular matrices (ECMs), the 96-well plate was
coated with 6 μg/ml of fibronectin, vitronectin, Geltrex, or 4 μg/ml
of BSA (in 50 μl/well of 1× TBS) and incubated overnight at 37°C
before PI immunoassay according to the manufacturer’s instructions.
Invasion Assay
For the invasion assay, 6.0 μg/ml of Geltrex, vitronectin, or fibro-
nectin (in 50 μl of TBS, incubated overnight at RT) was coated to
the upper compartment of 8.0-μm pore Transwell inserts (Corning
Costar, New York, NY). A total of 1 × 106 cells/ml were added to the
upper “Costar” compartment (after 24 hours of starvation of medium
supplements). To the lower compartment, 650 μl of NBMsupplemented
with 10 μg/ml platelet-derived growth factor (PDGF-AB) (Miltenyi
Biotec, UK) was added and incubated at 37°C for 5 hours. The hema-
tologic stain, Diff-quick (Bio-Rad, Hertfordshire, United Kingdom)
was used to assay the invaded cells on the basal layer of the Transwell
insert. The mean number of invasive cells was quantified using an
Olympus IX71 research inverted system microscope (Olympus, Essex,
United Kingdom).
Statistical Analysis
Student’s t test was used for statistical evaluation (P < .005). All
data presented are representative of three independent experiments
performed in triplicate (n = 3). All values are shown as arithmetic
means ± standard errors of the mean (SEM).
Results
CD133+ve and CD133−ve Cell Fractions Display Similar
Stemness and Differentiation Capacities
To confirm the presence of stem cells and the capacity for multi-
lineage differentiation, qualitative and quantitative immunofluorescence
was performed. Sox-2, Nestin, Olig-2, and Musashi-1 are frequently
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used asmarkers for an undifferentiated state. Analyzing Sox-2 expression
by flow cytometry, we detected 93.5% ± 1.425% Sox-2+ve cells in the
CD133+ve cell fraction. Similarly, CD133−ve cells displayed 92.34% ±
1.44% Sox-2+ve cells. Using fluorescence immunocytochemistry,
strong Sox-2 levels were also identified in both cell fractions. By flow
cytometry, the CD133+ve and CD133−ve cell fractions were 95.3% ±
0.45% and 95.4% ± 0.523% Olig-2+ve, respectively. Olig-2 positivity
was also detected with fluorescence immunocytochemistry localized
within the cytoplasm. Nestin expression was restricted to the cell
bodies of both cell fractions. By flow cytometry, we detected 90.4% ±
0.551% Nestin+ve cells in the CD133+ve fraction and 81.7% ± 1.21%
Nestin+ve cells in the CD133−ve cell fraction. We also identified
Musashi-1+ve cells typically localized to the cytoplasm of CD133+ve
and CD133−ve cells. Flow cytometry detected 96.9% ± 0.205%
Musashi-1+ve cells in the CD133+ve fraction and 87.4% ± 3.58%
positivity in the CD133−ve fraction. Although both fractions displayed
stemness, the CD133−ve fraction displayed statistically significant
decreased expression with Nestin and Musashi-1 but not with Olig-2
and Sox-2.
We next evaluated the multipotency of CD133+ve and CD133−ve
cell fractions by inducing differentiation and expansion into neuronal,
astrocytic, and oligodendrocytic lineages. After 3 days of expansion,
fluorescent immunocytochemistry showed immunoreactivity for
GFAP (astrocytes), βIII-tubulin (neurons), and Olig-4 (oligodendro-
cytes) in both cell fractions. Stemness and differentiation analysis are
summarized in Figures 2 and 3.
CD133/1 Expression under Atmospheric and
Hypoxic Oxygen Conditions in IN699
The expression of CD133 in the IN699 cells cultured under atmo-
spheric and hypoxic culture conditions was assessed by flow cytom-
etry. The percentage of the cell population expressing CD133 as
well as the fluorescence fold expression under atmospheric and
hypoxic culture conditions assessed by flow cytometry is shown in
Figure 4. Hypoxia caused a significant increase in the levels of
CD133 plus a 30-fold increase in CD133 expression (expressed as
fluorescence fold change) in comparison to the IN699 cells cultured
under atmospheric growth conditions. The cellular location of
CD133 and the expression level patterns under hypoxic and atmo-
spheric oxygen conditions were further confirmed by fluorescence
immunocytochemistry as shown in Figure 5. The cellular location
of CD133 was typically identified as spanning the plasma membrane
under both oxygen tensions with a significant increase in CD133
expression with hypoxia.
DNA Copy Number Analysis in IN699 Parental, CD133+ve,
and CD133−ve Cell Populations
Genomic copy number profiles generated for IN699 parental cells
and for the CD133+ve and CD133−ve fractions were essentially iden-
tical, allowing for interarray variation (Figure 6). All of the three cell
populations displayed multiple copy number aberrations involving all
chromosomes and indicating a complex tumor karyotype. With the
exception of monosomy 4, all autosomes demonstrated interstitial
Figure 2. The percentage mean (percentage-gated expression) of cells displaying positivity for each antigen for the CD133+ve (blue) and
CD133−ve (red) cell fractions, cultured under hypoxia (3% O2 and 5% CO2), analyzed by flow cytometry. Student’s t test was used for
statistical evaluation (*P < .005). All data presented are representative of three independent experiments performed in triplicate (n = 3).
All values are shown as arithmetic means ± standard errors of the mean.
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regions of either homozygous loss, loss, gain, and/or high copy gain.
A summary of gains and losses is given in Table W1, including cyto-
band locations and sizes of aberrations.
Expression Levels of the CD133 Glycoprotein Are
Inversely Proportional to HIF-1α
HIF-1α and HIF-2α are essential transcription factors moderating
changes in gene expression in response to hypoxia. HIF-1α, HIF-2α,
and CD133 antigen and glycoprotein levels were determined in the
parental cell culture with decreasing oxygen tension during a 96-hour
period. The percentage mean of the HIF-2α antigen remained signifi-
cantly (P < .005) elevated, with decreasing oxygen with positivity rang-
ing from 98.0% ± 0.24% to 99.4% ± 0.135%. In contrast, HIF-1α
positivity rapidly declined from 76.7% ± 5.5% to 2.7% ± 0.38%.
On the analysis of antigen expression (fluorescence fold expression), a
positive correlation between HIF-2α and CD133 was observed with
decreasing oxygen tension (P < .005) displaying a cumulative increase
between HIF-2α and CD133. In contrast, an inversely proportional
relationship between CD133 and HIF-1α was seen (P < .005); as
the levels of CD133 increased with hypoxia, the levels HIF-1α
decreased. It is clear that a relationship between HIF-2α and CD133
exists, which may be implicated in the regulation of the stem cell
phenotype with decreasing oxygen tension. Decreasing oxygen tension
effects HIF-1α but is not mirrored by HIF-2α in IN699. The expres-
sion levels of HIF-2α were seen to be independent of oxygen tension
and culture conditions. The relationship between CD133 and HIF-1α
and HIF-2α respectively are summarized in Figure 7.
Cell Cycle and Proliferation Analysis of IN699 and CD133+ve
and CD133−ve Cell Fractions Derived Therefrom
On comparison of both oxygen tensions, the G1 phase represented
most of the cycling cell population. Under atmospheric conditions,
the G1 phase represented 81% ± 0.328% of the cell population.
However, with decreasing oxygen tension, the percentage of active
cells within the G1 phase decreased to 71% ± 0.88%. The S phase
and G2/M phases of each tension were virtually equal; with increased
oxygen tension, the cycling cells in the S phase and the G2/M phase
are 8.6% ± 0.322% and 9.4% ± 0.026%, respectively, and with
reduced oxygen, the S phase and the G2/M phase cell population
numbers increased to 13.7% ± 0.12% and 14% ± 0.85%, respec-
tively. For both the CD133+ve and CD133−ve cell fractions, the
G1 phase represented most of the actively cycling cell populations,
displaying values of 82.32% ± 1.46% and 78.73% ± 1.43%, respec-
tively. The percentages of cycling cells for both cell populations within
S and G2/M phases were virtually equal. The S and G2/M phases for
the CD133+ve fraction displayed 8.0867% ± 1.069% and 9.15% ±
0.35%, respectively. The S and G2/M phases for the CD133
−ve cell
fractions were 8.92% ± 0.73% and 10.71% ± 0.19%, respectively.
The proportion of actively cycling cells within the S phase differed
between the two oxygen tensions. Under atmospheric growth condi-
tions, we observed the PI to be 0.148 ± 0.0074; this value increased
to 0.168 ± 0.016 with decreasing oxygen tension. These PIs confirm
the results of the cell cycle analysis; the proportion of the S-phase
parental cells with decreased tension surpasses those with increased
oxygen tensions, implicating hypoxia or HIFs in the modification
of proliferation (Figure 8, A and B). The proportion of actively cycling
Figure 3. Fluorescence immunocytochemistry of isolated CD133+ve and CD133−ve cells characterized with stem cell markers and
markers of multilineage differentiation. The cellular location of Nestin seems to be within the cytosol and cellular processes of both
isolated cell cultures (A and B). GFAP was highly expressed in both cell types, localized within the cytoplasm and cellular processes
(C and D). Fluorescence staining for Olig-4 (E and F) was also observed within both cell cultures, primarily located around the periphery
of the nucleus. Staining for stemness and multilineage differentiation are shown in green (AlexaFluor 488) and counterstained with
Hoescht blue.
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cells within the S phase differed between the two cell fractions. These
PIs correlate with the results of the cell cycle analysis because there was
only a marginal disparity between the CD133+ve and CD133−ve
cells with regard to the S phase of the cell cycles. We observed a
PI of 0.111 ± 0.00715 with regard to the CD133+ve fraction and
0.098 ± 0.00408 for the CD133−ve cells (data not shown). The PI
of the parental culture showed substantial differences when cul-
tured in the presence of varying ECMs and oxygen tensions (Figure 8,
A and B). Vitronectin induced the greatest proliferation modifica-
tions. Under atmospheric conditions, the index was observed at
0.193 ± 0.0132; however, with decreasing oxygen tension, the index
decreased to 0.130 ± 0.00165. Similarly, fibronectin also induced a
PI of 0.130 ± 0.00346 with normoxia. However, with decreasing
oxygen tension, the PI was observed at 0.181 ± 0.056. Although
Geltrex induced the least-variant modifications between oxygen ten-
sions, this ECM stimulated the highest index with hypoxia (0.141 ±
0.00385). These results indicate that cell proliferation increases with
increasing oxygen tensions in the presence of ECMs, suggesting that
cell adhesion upregulates DNA synthesis. The CD133+ve population
displayed the highest PI values for each ECM in comparison to the
CD133−ve fraction (Figure 8). Of the ECMs investigated, BSA (the
control sample) instigated the highest PI at 0.195 ± 0.00465, followed
by Geltrex at 0.161 ± 0.0098. Vitronectin and fibronectin induced an
almost identical PI response at 0.109 ± 0.00524 and 0.104 ±
0.00507, respectively. Similarly, the highest PI for the CD133−ve
fraction was also induced with BSA (control) at 0.161 ± 0.00458
(17% less than the CD133+ve fraction, P < .005), followed by Geltrex
at 0.144 ± 0.0045 (10% less than the CD133+ve fraction, P > .005).
The PI for vitronectin decreased by 0.01 ± 0.00049 for the CD133−ve
cells, in comparison to the CD133+ve fraction, and in a similar
response to the CD133+ve cells, fibronectin resulted in the least sig-
nificant ECM at 0.00872 ± 0.004.
Propensity of Cell Attachment Increases with Normoxia
An increased propensity of cell attachment was observed with
increasing normoxia. Of the ECMs investigated, fibronectin pro-
duced the highest attachment rate at 1.604 ± 0.025, followed by
vitronectin (1.584 ± 0.038) and BSA (0.987 ± 0.06). The lowest cell
adhesion rate was produced with Geltrex (0.626 ± 0.017). Cell attach-
ment rates decreased significantly with decreasing oxygen tension. Of
the ECM proteins investigated with hypoxia, vitronectin produced
the highest adhesion rate (0.645 ± 0.035, P < .005), followed by
fibronectin (0.615 ± 0.015, P < .005) and BSA (0.504 ± 0.016,
Figure 4. (A) Percentage mean (percentage-gated expression) of
the parental IN699 cells displaying positivity for the CD133 antigen
under atmospheric and hypoxic oxygen tensions as analyzed by
flow cytometry. (B) Mean amount of CD133 antigen expression
as shown by an increase in fluorescence fold intensity (i.e., overall
fluorescence level of the total cell population) in the parental pedi-
atric GB cell culture (IN699) under atmospheric and hypoxic cul-
ture conditions as analyzed by flow cytometry. Student’s t test
was used for statistical evaluation (P < .005). All data presented
are representative of three independent experiments performed
in triplicate (n = 3). All values are shown as arithmetic means ±
standard errors of the mean.
Figure 5. Characterization of the parental pediatric GB cell culture
(IN699) with CD133 (green) and counterstained with Hoescht blue
under atmospheric (A) and hypoxic (B) oxygen tensions with fluo-
rescent immunocytochemistry. The cellular location of CD133 was
typically identified as spanning the plasma membrane under both
oxygen tensions with a significant increase in CD133 expression
with hypoxia. Scale bar, 32 μm.
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P < .005). Again, the lowest cell adhesion rate was induced with
Geltrex (0.389 ± 0.021, P < .005). The propensity of cell attachment
is summarized in Figure 8. Quantification of the CD133+ve and
CD133−ve cell adhesion assays demonstrated an overall 6% elevated
propensity for cell adhesion within the CD133−ve cell fraction for
each ECM investigated, in comparison to the CD133+ve population.
Of the ECMs assayed, Geltrex induced the highest rate of attachment
for the CD133−ve population at 0.396 ± 0.00686, followed by vitro-
nectin at 0.377 ± 0.1 and BSA at 0.366 ± 0.017. The least instigative
adhesive ECMwas fibronectin (0.355 ± 0.0196). Adhesion analysis of
the CD133+ve fraction also showed Geltrex to instigate the highest
level of adhesion at 0.3856 ± 0.009, followed by vitronectin at
0.356 ± 0.058 and BSA at 0.347 ± 0.0786. Again, the lowest cell
adhesion was observed by fibronectin at 0.323 ± 0.0073. Quantifi-
cation of CD133 adhesion propensities is summarized in Figure 8.
Analyzing CD44 expression by flow cytometry, we detected 1.201% ±
0.135% CD44+ cells in the CD133+ve cell fraction and 1.503% ±
0.073% CD44+ cells in the CD133−ve cell fraction (Figure 8).
Hypoxia Increases the Invasive Propensity of IN699 Cells
Invasion propensity (IP — the innate propensity of cells to invade)
levels correlated with decreasing oxygen tension in the parental cell
culture. The ECM Geltrex produced the highest IP with a value of
40.4 ± 4.85, an increase of 73% than that observed under atmo-
spheric growth conditions (10.6 ± 3.09). With decreasing oxygen
tensions, fibronectin induced an IP of 18.6 ± 1.066, a 62% increase
than that observed with normoxia (7.067 ± 1.6). Although vitro-
nectin instigated the lowest IP of both oxygen tensions, the IP with
increasing oxygen tensions (5.213 ± 1.235) was 63.32% less than
that noted with hypoxia (14.21 ± 1.645; Figure 8).
CD133−ve Cells Show Greater Invasion Propensity than
CD133+ve Cells
The CD133−ve cell fraction possessed the most significant IP (P <
.005) for each ECM investigated, supporting the notion of a possible
positive correlation between adhesion and invasion. The highest
CD133−ve cell IP was observed with vitronectin at 84 ± 12, 74%
Figure 6. An overview of the DNA copy number alterations in IN699 for (A) CD133+ve and (B) CD133−ve cell fractions. Green blocks
indicate regions of chromosome gain and red blocks regions of loss.
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Figure 7. (A) Percentage mean (percentage-gated expression) of the parental pediatric GB cell culture (IN699) expressing the antigens
CD133, HIF-1α, and HIF-2α at the following time points: 0, 24, 48, 72, and 96 hours with relation to the incubation period with hypoxia.
Although the levels of HIF-2α remain constant with hypoxia, the levels of HIF-1α seem to be inversely proportional to decreasing oxygen
tension. A positive correlation between decreasing oxygen tension and CD133 is also apparent. Student’s t test was used for statistical
evaluation (P < .005). All data presented are representative of three independent experiments performed in triplicate (n = 3). All values
are shown as arithmetic means ± standard errors of the mean. (B) Mean amount of CD133, HIF-1α, and HIF-2α antigen expression as
shown by an increase in fluorescence fold intensity (i.e., overall fluorescence level of the total cell population) in the parental pediatric
GB cell culture (IN699) at the following time points: 0, 24, 48, 72, and 96 hours with relation to the incubation period with hypoxia. A
positive correlation between HIF-2α and CD133 was observed with decreasing oxygen tension. However, in contrast, an inversely pro-
portional relationship between CD133 and HIF-1α with decreasing oxygen tension can be seen. Student’s t test was used for statistical
evaluation (P < .005). All data presented are representative of three independent experiments performed in triplicate (n = 3). All values
are shown as arithmetic means ± standard errors of the mean.
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Figure 8. (A) PI analysis of the parental pediatric GB cell culture (IN699) with BrdU under atmospheric and hypoxic growth conditions. (B)
PI analysis of CD133+ve and CD133−ve cells with BrdU with hypoxia. (C) Cell attachment propensity analysis of the parental pediatric
GB cell culture (IN699) under atmospheric and hypoxic oxygen tensions, cultured in the presence of vitronectin, fibronectin, Geltrex, and
BSA (control sample). (D) Cell attachment propensity analysis of CD133+ve and CD133−ve cell fractions, cultured in the presence of
vitronectin, fibronectin, Geltrex, and BSA (control sample) under hypoxic oxygen tension. (E) Invasion propensity analysis of the parental
pediatric GB cell culture (IN699) under atmospheric and hypoxic oxygen tensions, cultured in the presence of vitronectin, fibronectin,
and Geltrex. (F) Invasion propensity analysis of isolated CD133+ve and CD133−ve cell fractions, cultured in the presence of vitronectin,
fibronectin, and Geltrex with decreasing oxygen tensions. (G) PI analysis of the parental pediatric GB cell culture (IN699) under atmo-
spheric and hypoxic oxygen tensions, cultured in the presence of vitronectin, fibronectin, Geltrex, and BSA (control sample). (H) PI anal-
ysis of isolated CD133+ve and CD133−ve cell fractions, cultured in the presence of vitronectin, fibronectin, Geltrex, and BSA (control
sample) with decreasing oxygen tension. All data presented in Figure 7 are representative of three independent experiments performed
in triplicate (n = 3). All values are shown as arithmetic means ± standard errors of the mean. Student’s t test was used for statistical
evaluation (P < .005).
150 A Prominin-1–Rich Pediatric Glioblastoma Donovan et al. Translational Oncology Vol. 5, No. 3, 2012
more invasive than the CD133+ve cells with vitronectin (22.4 ±
10.8). The CD133−ve cells were seen to be 75% more invasive than
the CD133+ve cells when assayed with fibronectin (35.5 ± 7.3 and
9.2 ± 2.96, respectively) and 52% more invasive when assayed
with Geltrex (42.56 ± 5.369 and 20.5 ± 7.17, respectively). Ana-
lyzing GD3 and acetylated GD3 expression by flow cytometry,
we detected 4.225% ± 0.61% GD3+ cells and 15.04% ± 0.073%
GD3A+ cells in the CD133+ve cell fraction and 4.48% ± 1.09%
GD3+ cells and 24.86% ± 4.3% GD3A+ cells in the CD133−ve frac-
tion (Figure 8).
Discussion
The role of CD133 as a CSC marker is both enigmatic and contro-
versial. Any evidence pointing toward a specific functional role of
CD133 may be significant in determining whether CD133 may
be appropriate as a CSC or “tumor-initiating cell” marker. Moreover,
CD133 has not yet been correlated to a contributing role in “cancer
stemness” [21] owing to the lack of knowledge surrounding the glyco-
protein. To determine a possible link between CD133 expression and
biologic function, the biologic behavior of CD133+ve and CD133−ve
cells with different oxygen tensions must be ascertained. Using a
pediatric GB containing unprecedentedly high levels of CD133+ve
cells as a study model, we have attempted to correlate CD133 expres-
sion with cellular phenotype and biologic behavior.
Brain tumor stem cells (BTSCs) are characterized by 1) the ability
to self-renew, 2) the capacity to initiate brain tumors, and 3) the abil-
ity to differentiate into cells of neuronal, astrocytic, and oligo-
dendroglial lineage [22,23]. After isolation, CD133+ve cells were
observed to coexpress (to a very high degree) Musashi-1, Nestin,
Olig-2, and Sox-2. Musashi-1, a cytoplasmic antigenic marker of
early development, indicates a neural origin [24]. Therefore, CD133+/
Musashi-1+ BTSCs resemble the phenotype of NSCs during early cor-
tical development [25]. This finding is supported by the coexpression of
CD133 andMusashi-1, indicating an NSC characteristic of CD133+ve
cells [26]. Moreover, Musashi-1 expression is of functional significance
for preserving self-renewal and multipotency in stem cells [27]. GB
cells that express high levels of Musashi-1 display significantly higher
levels of Notch-1 in comparison to cells with less Musashi-1 [28].
Hyperactivation of Notch-1, through Musashi-1, results in tumorigen-
esis and the maintenance of an immature phenotype [27], which may
begin to explain the elevated PI observed in the CD133+ve cells, in
comparison to the CD133−ve cells.
In the present study, the CD133+ve cells indicated a neural origin,
established by the CD133+/Nestin+ phenotype, because Nestin is
produced by NSCs in the mammalian CNS during development
to preserve the rapid self-renewal of NSCs [29]. Moreover, down-
regulation of the Nestin protein is associated with NSC differentia-
tion [30]. The production of Nestin by NSCs also makes this antigen
a marker of proliferation because it is associated with the hyperacti-
vation of N-myc [31]. In the present study, the IN699 CD133+ve
cells displayed upregulated expression of Nestin in comparison to
the CD133−ve cell fraction, which may account for the marked dif-
ference in PIs between the two populations.
During early embryonic CNS development, the basic helix-loop-
helix transcriptional repressor protein, Olig-2, plays a pivotal role in
maintaining NSCs and progenitor cells in a state of continuous rep-
lication. Of the IN699 CD133+ve and CD133−ve cell fractions,
almost all cells (approximately 95%) were positive for Olig-2. Similar
findings have been previously reported, demonstrating 98% of GB
CD133+ve cells to be positive for Olig-2 [32]. Many research groups
have shown that all high-grade malignant gliomas, independent of
histologic type, contain Olig-2+ve cells [32–36]. The expression
pattern of Olig-2 is therefore not conserved to a particular subset
of cells, explaining the IN699 CD133+/Olig2+ and IN699 CD133−/
Olig2+ phenotypes observed, indicating neuronal and oligodendroglial
lineages [32,35]. The presence of Olig-2 may be of significance to
“stemness” because it has been directly linked to cyclin-dependent
kinases implicated in the control of the p21 gene [37]. The repression
of p21 byOlig-2 results in the up-regulation of DNA synthesis, increas-
ing the levels of PCNA [37] correlating with the high expression levels
of PCNA observed in both the IN699 CD133+ve and CD133−ve cells,
98.4% and 98.1%, respectively.
Sox-2 is associated with the development of NSCs within the
CNS; therefore, CD133+/Sox-2+ BTSCs may resemble the pheno-
type of NSCs [38]. The transcription factor Sox-2 serves a functional
role in sustaining the growth and renewal of NSCs. Silencing of Sox-2
in GB cells has been shown to attenuate the expression of Ki67,
implicating Sox-2 with cell cycle control [38], thus supporting our
observed correlation of Sox-2 and Ki67 expression in CD133+ve cells,
maintaining rapid cell cycle turnover and upregulated proliferation
rates. Sox-2 expression has been documented in many malignant
tissues [39–44]. In addition, Sox-2 was identified not only to be
expressed in NSCs but also in early progenitor cells [38]. Because
the IN699 cells were cultured in NBM, optimized to support and
maintain the growth of stem and transiently dividing progenitor cells,
this may explain why Sox-2 is present in the IN699 CD133−ve frac-
tion. Therefore, instead of indicating “stemness,” Sox-2 may be indic-
ative of early progenitors. This finding correlates with the decreased
expression levels of Ki67 observed in the IN699 CD133−ve cells. A
similar expression pattern of Sox-2 and Ki67 has been reported in
CD133+ve and CD133−ve GBM cells when cultured under NSC-
specific cell culture conditions [45]. Moreover, the expression of
Sox-2 may decrease rapidly in cells maintained under differentiating
conditions [38], further supporting the notion that the IN699
CD133−ve cells are early progenitor cells.
The stage-specific embryonic antigen (SSEA-1/LEX)/CD15 is said
to positively identify tumor stem cells or tumor–initiating cells in
human GBs [46]. However, in the present study, the isolated
CD133+ve and CD133−ve cell fractions displayed little expression
(approximately 1%) for CD15, raising the possibility that CD15
may not be a universally enriched antigenic marker for BTSCs.
CD15 has been implicated in the metastatic spread of cancer cells by
functioning in both homophilic binding and as a ligand for P-selectin
and E-selectin on vascular endothelium [47]. The absence of the CD15
antigen in the IN699 CD133+ve and CD133−ve cell fractions is con-
sistent with the previous explanation for the general failure of intrinsic
human brain tumors to metastasize, by preventing the adhesion of
neoplastic glia to “target” organ endothelium outside the CNS [48].
The lineage commitment and differentiation stages of gliomas are
unclear [48]. Although it is uncommon for a single glioma to exhibit
the entire range of cell types generated by a NSC, gliomas are often
composed of multiple cell types such as astrocytes and oligodendro-
cytes [49]. In the present study, pluripotency was confirmed by the
expression of βIII-tubulin (neuronal), GFAP (astrocytic), and O4
(oligodendrocytic) lineage markers. These findings are consistent
with the research conducted by Beier et al.; a sphere derived from
a single CD133+ve cell displayed positivity for the three neural line-
ages, contributing a link to the cancer “stemness” connected to the
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glycoprotein [16]. However, whether CSC-derived differentiated
neoplastic cells can actually fulfill neural functions has yet to be ad-
dressed. Isolated IN699 CD133−ve cells were also observed to exhibit
neural lineage. These observations suggest that the heterogeneity
within gliomas may be a result not only of the NSC but also of the
neural progenitor cells [49]. If correct, this would explain the presence
of mixed cell gliomas, arising from the transformation of a single
bipotential cell [49,50], plus the blocked differentiation phenomenon
[51]. Progenitor cells, activated with GB signal transduction proteins
Akt and kRas, have also been reported to give rise to brain tumors in
rodents with histologically similar characteristics to GBs [52]. Alter-
natively, the expression of the lineage-specific marker may not be a
result of cell type; instead, it may indicate the differentiation stage(s)
characteristic of glioma cells and the normal glial genesis hierarchy.
Local oxygen concentrations can also directly influence stem cell
self-renewal. An attractive notion is that stem cells, particularly in
long-lived animals, benefit from residing in hypoxic niches where
oxidative DNA damage may be reduced [13]. In the present study,
CD133 expression increased with decreasing oxygen tension. Further-
more, the percentage-gated expression of CD133 antigens was observed
to positively correlate with the increasing numbers of HIF-2α. Recent
reports have identified molecular mechanisms whereby HIFs directly
modify cellular differentiation and stem cell functions. Therefore, a
relationship between HIF-2α and CD133 must exist and is implicated
in the regulation of the stem cell phenotype. In the present study, HIF-
2α was seen to increase under hypoxic conditions along with increasing
CD133 expression. Thus, HIF-2α may regulate CD133 expression,
whereas HIF-1α, which decreased under 3% oxygen conditions, seems
to counterbalance CD133 regulation. Moreover, hypoxia has been
shown to block NSC differentiation in a Notch-dependent manner
[53]; furthermore, HIF-2α promotes c-Myc transcriptional activity,
further stabilizing an immature cell state [54]. Indeed, HIF-1α has been
shown to antagonize c-Myc transcriptional activity under hypoxia,
resulting in the up-regulation of p21 and cell cycle arrest, whereas
HIF-2α promotes c-Myc function, through cyclin D2, inducing cell
cycle progression [55], which may explain the down-regulation of
HIF-1α observed with increasing levels of CD133 and HIF-2α.
Although hypoxia induced a high invasive propensity of the paren-
tal IN699 culture and the CD133−ve cells, cellular adhesion (i.e., the
number of cells attached) was decreased. Quantification of cell attach-
ment demonstrated that, although the CD133−ve cells were observed
to increase in number of cells attached with all of the ECMs analyzed
(significantly vitronectin and fibronectin), in relation to the IN699
CD133+ve cells, the number of cells attached was not significant.
These findings suggest that the CD133 glycoprotein does not act as
an adhesion molecule. In contrast, the microenvironment does seem
to exert a significant influence on cellular adhesion, with the number
of attachments significantly decreasing with hypoxia. Quantitative cell
analysis of the IN699 parental culture showed a significant decrease in
cellular attachment to vitronectin and fibronectin under hypoxia. In
concert with this adhesion to vitronectin and fibronectin by MDA-
MB-231, breast cancer cells were reduced with hypoxia and little dif-
ference in the adhesiveness of these cells to either substrate was also
noted [56]. It therefore seems that decreasing oxygen tension induces
a decline in cellular adhesion. It is well recognized that cells may either
divide or transiently arrest from the cell cycle and invade [57], suggest-
ing that the rate of proliferation is inversely proportional to invasion.
Characterization of CD133−ve cells with HIF-1α displayed an up-
regulation in overall percentage and fluorescence intensity in compari-
son to the CD133+ve cells. Hypoxia (through HIF-1α activation) is
also known to increase the expression of the CXCR4 gene, a chemokine
receptor associated with tumor progression and metastatic spread [58].
Therefore, the up-regulation of HIF-1α observed in our studies may
contribute to the increased invasion seen in the CD133−ve cells.
Integrins are known to play a major role in cell adhesion to the
ECM. It has been documented that, by decreasing oxygen, the levels
of αv integrin reduce [56]. This down-regulation of αv revealed a mech-
anism by which hypoxia may inhibit adhesion. Characterization of the
IN699 CD133+ve and CD133−ve populations with CD44, a receptor
for hyaluronic acid, revealed low levels of antigen expression in both
fractions. Similar findings where low oxygen levels downregulated the
expression of cell adhesion molecules, including CD44, have also been
reported [59]. Down-regulation of cellular adhesion may also cause
integrin switching, enhancing the expression of integrins, which favor
a particular development stage. Hypoxia may therefore induce remodel-
ing of the ECM to favor invasion, as noted in our findings. Furthermore,
the switching of integrins with regard to biologic activities demonstrated
a positive correlation between adhesion and proliferation. To produce
an increase in adhesion in all of the populations quantified, the ECM
was also observed to induce an upregulated PI. If this is indeed correct,
the proliferation data suggest that the IN699 CD133+ve cells are
associated with β1-integrin because of β-integrin’s high association with
adhesion and proliferation within this cellular fraction. β1-Integrin–
expressing cells also display positivity for the CD133 [60].
With increasing differentiation, the AC133 epitope decreases in a
manner positively correlated with the loss of clonogenicity [61].
Moreover, in colon carcinoma cells, AC133 can be masked on cellular
differentiation [61]. Consistent with these findings, Campos et al.
[62] also reported a loss of AC133 immunoreactivity on differentia-
tion without altering the CD133 mRNA. This suggests that protein
folding may occur because of differential glycosylation, masking spe-
cific epitopes of CD133. Although this evidence suggests that CD133
expression is not restricted to CSC, it does imply that glycosylation
supports the hierarchical model for tumor initiation. In addition,
CD133−ve glioma cells have also been shown as capable of giving rise
to CD133+ve cells [15], supporting our findings that CD133+ve and
CD133−ve cells do not remain consistent in expression. Our data
therefore suggest that, although on characterization with the
AC133 antibody it seems there has been a “loss” of “stemness,” dif-
ferential glycosylation may actually take place, promoting not only
differentiation but also an increased invasion propensity, until appro-
priate microconditions ensue for the AC133 epitope to present itself
again. The CD133/1 (AC133) antigen has been identified as a glyco-
sylated protein [63]. The mechanisms involved in tumor malignancy
are maintained either directly or indirectly by N - or O-linked glyco-
sylation or by the surrounding gangliosides [64]. Hakomori [65]
demonstrated that CD133 can be saturated by gangliosides, thus
affecting the phenotype of CD133. Both the IN699 CD133+ve
and CD133−ve fractions displayed a high level of positivity for the
ganglioside GD3, inferring that GD3 does not play a functional role
in the biologic behavior of CD133. However, the amount of GD3 in
the cell membrane at any one time may determine functional roles
[66]. In contrast, it is highly likely that the glycosylation of the
CD133 glycoprotein has a modulatory role in control of behavior.
Alternatively, glycosylated CD133 (AC133) may sequester the GD3
antigen to the N-terminal of the protein, inducing the extracellular
formation of endoglycosidases, resulting in the de-N -glycosylation of
the CD133molecule and the switching of integrin receptors, promoting
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the invasive phenotype. Taïeb et al. [67] proposed that the extracellular
N-terminal domain of the CD133 protein may undergo conformational
alterations depending on the composition of membranous gangliosides,
thus alterations in the membrane composition may be accountable for
masking the AC133 epitope.
It has been suggested that tumorigenic CD133+ve cells are main-
tained in a dormant state but spontaneously enter the cell cycle to give
rise to angiogenic CD133−ve daughter cells [45]. This implies that
tumorigenesis is initiated by asymmetric cell divisions of the CD133+ve
cells. However, on characterization of the IN699 CD133+ve fraction, we
noted that almost all of the cells were Ki67-positive; therefore, one would
assume that the CD133+ve cells are not maintained in a dormant state,
at least under in vitro conditions. The spontaneous formation of
CD133−ve cells might then support the stochastic tumor initiation
model; hence, it is unlikely that the formation of either cell fraction
is “spontaneous.” The formation may in fact be determined by the
microenvironment contributing to the differential glycosylation and
reformation of the CD133 epitope. Our data suggest that the HIF-2α
subunit contributes to the proliferation rate and maintenance of
CD133+ve cells. Our data show that the CD133+ve and CD133−ve
fractions are affected by different HIFs. During a 96-hour time course,
from high- to low-oxygen tensions, the mean amount of HIF-1α anti-
gen expression was observed to be inversely proportional to HIF-2α.
Carroll and Ashcroft [68] also noted a down-regulation of HIF-2α in
MCF-7 breast carcinoma cells, resulting in an up-regulation in HIF-
1α–dependent vascular endothelial growth factor stimulation.
A number of previous studies have distinguished CD133+ve and
CD133−ve cell populations in adult glioma based on their molecular
signatures and phenotypic behavior [8,16,69,70]. In most cases,
CD133+ve and CD133−ve cells had significantly different transcrip-
tional profiles, generated either by global expression analysis or with a
discrete panel of markers. However, differential genomic analysis of
CD133+ve and CD133−ve factions has not been described in glioma.
Our observation that IN699 CD133+ve and CD133−ve cells had
identical genomic imbalances concurs with a recent report of indistin-
guishable array comparative genomic hybridization profiles in CD133+ve
and CD133−ve isolates from colorectal carcinoma cell lines [70].
Our research documents a direct link between decreasing oxygen ten-
sion and glycosylated CD133 (AC133) expression.We have also shown
that the in vitro hypoxic microenvironment facilitates a role in the
in vitro behavior of pediatric GB cells. Therefore, the AC133 epitope
of CD133may characterize areas of low oxygen and an undifferentiated
phenotype in tumor tissues, correlating with the radioresistance of
tumor cells and the associate poor clinical outcome in patients [7,71]. In
this article, we have reported a hitherto undocumented high expression of
CD133+ve cells in a cultured pediatric GB that have been used further as a
studymodel to investigate cellular biologic behavior andmolecular profiles
of CD133+ve and CD133−ve cells. Distinct biologic differences were
obvious between the CD133+ve and CD133−ve cells fractions: 1) CD133−ve
cells displayed an increased invasive propensity in comparison to theCD133+ve
cells; 2) CD133+ve cells may be inversely linked to invasion, displaying
an increased PI in comparison to CD133−ve cells; and 3) CD133 does
not facilitate a role in cellular adhesion. However, our observations
also indicated identical genomic imbalances between CD133+ve and
CD133−ve fractions. Our results also suggest plasticity in CD133
expression. “Spontaneous” formation of the CD133 phenotype and
microenvironmental influence suggests that CD133 is not a definitive
brain tumor CSC marker. Its presence in pediatric GB may, however,
significantly define biologic behavior and subsequent clinical outcome.
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Table W1. Genomic Losses and Gains in IN699.
Cytoband Location Event Region Length (bp) Genes
1p36.33 CN gain 596,963 11
1p36.11 – p33 CN gain 21,599,034 334
1p33 – p32.3 CN gain 5,086,703 58
1p31.1 – q11 CN gain 47,102,085 302
1q21.1 – q21.3 CN gain 5,989,293 135
1q21.3 – q23.1 CN gain 4,654,974 148
1q25.3 CN gain 3,653,976 30
1q31.3 – q32.1 CN gain 8,003,229 107
1q32.1 – q42.11 CN loss 17,363,747 107
1q42.12 – q44 CN loss 17,861,791 115
1q44 CN loss 3,504,889 66
2p25.3 – p25.2 CN loss 6,150,286 22
2p23.3 – p23.2 CN gain 2,403,889 38
2p22.3 – p16.3 CN gain 12,807,038 83
2p16.2 – p16.1 CN gain 3,492,096 27
2p16.1 – p12 CN gain 17,740,336 143
2p12 – p11.2 CN gain 6,370,822 55
2q11.1 – q14.1 CN gain 21,598,724 176
2q14.1 – q14.3 CN gain 7,007,493 25
2q14.3 CN gain 4,061,048 18
2q21.3 CN gain 223,691 4
2q24.1 – q24.2 CN gain 6,252,983 25
2q24.3 – q32.2 CN gain 24,640,768 136
3p26.3 – p24.3 CN loss 14,969,624 94
3p24.3 CN gain 153,663 3
3p24.3 – p21.31 CN loss 31,734,929 184
3p14.3 – q11.1 CN loss 33,801,099 73
3q11.2 – q12.2 CN loss 7,399,778 39
4p16.3 – p14 CN loss 37,951,466 189
4p13 – q32.3 CN loss 127,882,623 527
4q32.3 CN gain 233,115 2
4q32.3 – q35.2 CN loss 21,518,428 129
5p15.33 CN gain 3,603,755 34
5p13.3 – p13.1 CN gain 8,723,688 50
5q12.3 – q14.3 CN loss 22,947,949 143
5q33.3 – q35.2 CN gain 19,053,329 99
5q35.3 CN gain 3,802,280 63
6p25.3 – p24.2 CN loss 10,841,147 65
6p11.2 – q11.1 CN loss 3,207,171 2
6q11.1 CN gain 1,559,394 0
6q11.1 – q12 CN loss 7,643,209 8
6q14.1 CN loss 4,575,744 10
6q21 CN gain 1,047,103 8
6q21 CN gain 517,159 5
7p21.2 – p21.1 CN gain 1,478,677 3
7p15.2 – p15.1 CN gain 3,145,415 28
7p14.1 – p12.3 CN gain 7,550,255 59
7q11.22 CN gain 662,999 1
7q11.23 – q21.11 CN gain 12,666,389 89
7q35 CN loss 669,336 1
8p23.1 CN gain 4,407,582 76
8p23.1 – q11.21 CN gain 36,438,850 205
8q13.1 – q21.11 CN gain 7,585,870 41
8q21.12 – q21.13 CN gain 3,666,688 17
8q21.3 – q23.1 CN gain 15,423,079 82
8q23.3 – q24.22 CN gain 15,893,204 66
8q24.3 CN gain 6,101,253 114
9p24.3 – p21.1 CN loss 28,461,665 116
9p13.1 – q11 CN loss 12,872,313 35
9q21.33 CN gain 829,222 5
9q22.2 – q31.1 CN gain 10,284,608 107
9q31.3 – q33.1 CN gain 6,533,593 63
9q33.2 – q34.3 CN gain 18,005,802 329
10p12.1 – p11.23 CN gain 385,701 2
10q11.21 – q11.22 CN loss 5,683,600 62
10q21.3 CN loss 237,262 1
11p15.4 CN gain 1,179,717 21
11p15.2 – p15.1 CN gain 3,077,089 34
11p11.2 – p11.12 CN loss 3,161,065 15
11q14.1 CN loss 4,925,671 11
11q14.3 CN loss 548,824 3
11q21 CN gain 1,213,132 6
11q23.3 – q25 CN loss 15,945,313 134
Table W1. (continued )
Cytoband Location Event Region Length (bp) Genes
12p13.33 – q12 CN loss 41,094,862 336
12q14.1 CN loss 1,462,517 1
12q14.1 – q14.3 CN gain 3,499,207 20
12q24.31 CN gain 788,508 13
12q24.31 CN gain 1,899,515 24
13q11 – q12.3 CN loss 12,957,921 74
13q14.11 – q21.2 CN gain 15,927,992 110
13q21.2 – q31.1 CN loss 25,539,125 40
13q31.1 CN gain 52,493 1
13q31.1 – q31.3 CN gain 6,427,744 13
13q31.3 – q34 CN loss 21,435,167 96
14q11.1 – q13.1 CN loss 13,971,938 171
14q22.1 CN gain 1,600,129 20
14q23.2 – q23.3 CN loss 4,308,546 27
14q32.33 CN loss 1,513,172 11
15q11.2 CN loss 1,512,134 15
15q11.2 – q22.31 CN loss 41,678,197 449
15q24.1 CN gain 333,787 4
15q25.1 – q25.2 CN loss 3,270,540 30
15q26.3 CN gain 44,315 3
15q26.3 CN loss 666,735 11
16p13.3 CN gain 850,396 13
16p11.2 CN loss 2,045,883 10
16q21 CN loss 4,674,102 1
16q22.2 CN loss 337,574 1
17p13.3 CN loss 2,947,228 54
17p13.3 – p13.1 CN gain 7,226,737 197
17p12 – p11.2 CN gain 5,845,900 93
17p11.2 – p11.1 CN loss 1,620,116 12
17p11.1 – q11.1 CN gain 95,705 0
17q11.1 – q12 CN loss 7,794,880 111
17q25.1 – q25.2 CN gain 440,781 17
17q25.2 – q25.3 CN loss 6,376,544 115
18p11.32 – p11.31 CN loss 3,009,422 19
18p11.31 – q11.1 CN loss 12,249,665 55
18q11.2 – q22.2 CN loss 47,462,351 188
18q22.3 – q23 CN loss 9,205,484 32
19p13.3 CN gain 243,848 6
19p13.3 CN loss 3,334,196 121
19p13.11 – q11 CN loss 9,743,747 70
19q12 – q13.2 CN loss 13,538,594 237
19q13.31 CN loss 729,970 16
19q13.41 CN loss 1,110,621 31
20p11.21 – p11.1 CN gain 827,582 11
20p11.1 – q11.21 CN loss 3,551,079 5
20q13.2 – q13.33 CN gain 8,923,757 134
21p11.2 – q11.1 CN loss 2,403,370 6
21q22.2 – q22.3 CN loss 1,442,348 9
22q13.31 – q13.33 CN loss 3,810,101 45
Xq23 – q26.3 CN gain 18,509,992 166
Yp11.32 – q11.23 CN loss 27,177,529 191
Yq12 CN loss 395,226 3
